study assessing Post-exposure prophylaxis following high-risk contact with Ebola virus, using immunotherapies with monoclonal antibodies, in the eastern Democratic Republic of the Congo
Latest Information Update: 30 Dec 2021
At a glance
- Drugs Ansuvimab (Primary) ; Atoltivimab/maftivimab/odesivimab (Primary)
- Indications Ebola virus infections
- Focus Therapeutic Use
Most Recent Events
- 30 Dec 2021 New trial record
- 01 Dec 2021 Results published in the International Journal of Infectious Diseases